丁丙诺啡(Buprenorphine) - 药物靶点：κ opioid receptor x μ opioid receptor_在研适应症：阿片相关性障碍，鸦片依赖，阿片滥用_专利_临床

概要

基本信息

药物类型

小分子化药

别名

NanoBUP、丁丙诺菲、CAM2038

+ [6]

靶点

κ opioid receptor x μ opioid receptor

作用机制

κ opioid receptor激动剂(κ-阿片受体激动剂)、μ opioid receptor拮抗剂(μ-阿片受体拮抗剂)

治疗领域

神经系统疾病其他疾病

在研适应症

阿片相关性障碍鸦片依赖阿片滥用+ [2]

非在研适应症

镇痛肠易激综合征腰痛+ [4]

原研机构

OrphoMed, Inc.初创企业

在研机构

Braeburn, Inc.Mundipharma KK

Camurus AB

+ [4]

非在研机构

Titan Pharmaceuticals, Inc.

BioDelivery Sciences International, Inc.

OrphoMed, Inc.初创企业

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (2010-06-30),

慢性疼痛

最高研发阶段(中国)终止

特殊审评快速通道 (美国)、孤儿药 (美国)

登录后查看首次获批时间轴

结构

分子式C29H41NO4

InChIKeyRMRJXGBAOAMLHD-IHFGGWKQSA-N

CAS号52485-79-7

关联

378

项与丁丙诺啡相关的临床试验

NCT06574009 / Not yet recruitingN/A

Better Options for Chronic Cancer Pain: a SMART Study

This proposal is relevant to the 240,000 cancer survivors who continue to use opioids long after they have successfully completed treatment for cancer at the VHA, placing them at risk of opioid addiction and overdose, and other opioid-related problems. Yet, there are no programs at the VHA to help them find alternatives to opioids, nor evidence to inform the choice of interventions. This study will meet these needs by examining four interventions that are effective at reducing opioid use in patients with chronic musculoskeletal pain but have yet to be tested in cancer survivors on long term opioid therapy. The proposed work is relevant to the VHA Pain Office's mission to provide Veterans better pain management while limiting the risks of long-term opioid therapy and it aligns with VHA Research and Development's priority to examine clinical interventions for tapering opioids. Successful completion this project will keep VHA at the forefront of the battle against the opioid epidemic with a strategy that may be adapted to address the same needs in non-Veterans.

开始日期2025-04-01

申办/合作机构

VA Office of Research and Development

NCT04454411 / Not yet recruiting临床2期IIT

Brain Mechanisms of Cognitive Response to Pharmacotherapy in Opioid Use Disorder

This study will investigate the mechanisms of cognitive-behavioral response to medications used for relapse prevention in opioid use disorder (opioid addiction, OUD), through investigation of the neural circuits underlying key cognition functions. The study will use previously validated cognitive probes, functional Magnetic Resonance Imaging (fMRI), and novel extended-release injectable preparations of opioid partial agonist buprenorphine and antagonist naltrexone, in OUD patients to explain the individual heterogeneity of OUD treatment response.

开始日期2025-02-01

申办/合作机构

University of Pennsylvania

NCT05339256 / Not yet recruiting临床2期IIT

A Randomized, Controlled Trial of Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual in the Treatment of Opioid Use Disorder

This study will compare in-person induction and maintenance dosing of sublingual buprenorphine to induction and maintenance dosing of sublingual buprenorphine through comprehensive telehealth sessions and telehealth medication for opioid use disorder (MOUD).

开始日期2025-01-01

申办/合作机构

The New York State Psychiatric Institute

[+1]

100 项与丁丙诺啡相关的临床结果

登录后查看更多信息

100 项与丁丙诺啡相关的转化医学

登录后查看更多信息

100 项与丁丙诺啡相关的专利（医药）

登录后查看更多信息

9,360

项与丁丙诺啡相关的文献（医药）

2025-01-01·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Repeated lyophilization: A neo-method for urine-based reference materials preparation

Article

作者: Liu, Yu ; Zhi, Yujie ; Zhang, Zhen ; Hu, Jing ; Jin, Wenhui ; Liu, Wei ; Zheng, Qiongying ; Zhang, Wenping ; Lu, Jiayue ; Dou, Quanlu ; Chen, Hang

In urine drug testing, a cut-off value is often imposed to determine whether the sample is negative or positive. A matrix containing a reference substance helps counteract the adverse effects of the urine matrix across different laboratories to improve the consistency of final results. However, as a biological matrix, urine is prone to corruption and other problems that make it difficult to use as a reference sample. In this study, morphine, nitrazepam, lorazepam, buprenorphine, zolpidem, midazolam, diazepam, and clozapine commonly used in clinical practice were selected as target analytes, and the preparation process was further optimized to repeated lyophilization, in order to obtain more effective, stable, and accurate urine matrix reference materials (mRMs). The appropriate urine density (1.010-1.017 kg/m³) for preparing lyophilized samples was investigated through density determination. Conducting repeated lyophilizations resulted in a denser powder with reduced susceptibility to collapse and improved the quality of lyophilized urine samples. Lyophilized urine mRMs could be stored at room temperature for one month or under refrigeration conditions (4 ℃) for six months.

2025-01-01·CLINICA CHIMICA ACTA

Direct analysis in real time mass spectrometry (DART-MS/MS) for rapid urine opioid detection in a clinical setting

Article

作者: El-Khoury, Joe M ; Tran, Minh Nguyet ; Cassella-McLane, Gina ; Shang, Emily ; Choucair, Ibrahim

BACKGROUND AND AIMS:

Current laboratory methods for opioid detection involve an initial screening with immunoassays which offers efficient but non-specific results and a subsequent liquid chromatography-tandem mass spectrometry (LC-MS/MS) confirmation which offers accurate results but requires extensive sample preparation and turnaround time. Direct Analysis in Real Time (DART) tandem mass spectrometry is evaluated as an alternative approach for accurate opioid detection with efficient sample preparation and turnaround time.

MATERIALS AND METHODS:

DART-MS/MS was optimized by testing the method with varying temperatures, operation modes, extraction methods, hydrolysis times, and vortex times. The method was evaluated for 12 opioids by testing the analytical measurement range, percent carryover, precision studies, stability, and method-to-method comparison with LC-MS/MS.

RESULTS:

DART-MS/MS shows high sensitivity and specificity for the detection of 6-acetylmorphine, codeine, hydromorphone, oxymorphone, hydrocodone, naloxone, buprenorphine, norfentanyl, and fentanyl in urine samples. However, its performance was suboptimal for norbuprenorphine, morphine and oxycodone.

CONCLUSION:

In this proof-of-concept study, DART-MS/MS is evaluated for its rapid quantitative definitive testing of opioids drugs in urine. Further research is needed to expand its application to other areas of drug testing.

2024-12-31·ANNALS OF MEDICINE

The role of recovery peer navigators in retention in outpatient buprenorphine treatment: a retrospective cohort study

Article

作者: Nyaku, Amesika N. ; Giraldo, Arley ; Shah, Payal ; Zerbo, Erin

BACKGROUND:

Racial and ethnic disparities are evident in the accessibility of treatment for opioid use disorder (OUD). Even when medications for OUD (MOUD) are accessible, racially and ethnically minoritized groups have higher attrition rates from treatment. Existing literature has primarily identified the specific racial and ethnic groups affected by these disparities, but has not thoroughly examined interventions to address this gap. Recovery peer navigators (RPNs) have been shown to improve access and overall retention on MOUD.

PATIENTS AND METHODS:

In this retrospective cohort study, we evaluate the role of RPNs on patient retention in clinical care at an outpatient program in a racially and ethnically diverse urban community. Charts were reviewed of new patients seen from January 1, 2019 through December 31, 2019. Sociodemographic and clinical visit data, including which providers and services were utilized, were collected, and the primary outcome of interest was continuous retention in care. Bivariate analysis was done to test for statistically significant associations between variables by racial/ethnic group and continuous retention in care using Student's t-test or Pearson's chi-square test. Variables with p value ≤0.10 were included in a multivariable regression model.

RESULTS:

A total of 131 new patients were included in the study. RPNs improved continuous retention in all-group analysis (27.6% pre-RPN compared to 80.2% post-RPN). Improvements in continuous retention were observed in all racial/ethnic subgroups but were statistically significant in the non-Hispanic Black (NHB) group (p < 0.001). Among NHB, increases in continuous retention were observed post-RPN in patients with male sex (p < 0.001), public health insurance (p < 0.001), additional substance use (p < 0.001), medical comorbidities (p < 0.001), psychiatric comorbidities (p = 0.001), and unstable housing (p = 0.005). Multivariate logistic regression demonstrated that patients who lacked insurance had lower odds of continuous retention compared to patients with public insurance (aOR = 0.17, 95% CI 0.039-0.70, p = 0.015).

CONCLUSIONS:

RPNs can improve clinical retention for patients with OUD, particularly for individuals experiencing several sociodemographic and clinical factors that are typically correlated with discontinuation of care.

263

项与丁丙诺啡相关的新闻（医药）

2024-09-30

·BioSpace

Study Examining Use of Nalmefene HCI Injection for Opioid Overdose Reversal in Emergency Departments Concludes Observational Period

STAMFORD, Conn.--(BUSINESS WIRE)--Purdue Pharma has completed the first phase of a study examining the use of nalmefene hydrochloride (HCI) injection in real-world emergency department (ED) settings. Researchers are now conducting data analysis, with study results expected later this year. The research was funded by Purdue. Nalmefene hydrochloride injection is available as a 2mg/2mL (1mg/1mL) vial, and is an opioid antagonist indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids and in the management of known or suspected overdose. Nalmefene hydrochloride injection is contraindicated in patients with a known hypersensitivity to the product. 1 “We distribute nalmefene injection for no profit, as part of our commitment to providing opioid overdose treatments that can help save lives in communities across the country,” said Craig Landau, MD, President and CEO, Purdue. “We look forward to learning about the results of the study.” The Clinical Outcomes from Injectable Nalmefene in the Emergency Department (COINED) study is designed to measure the frequency of successful reversal of acute opioid toxicity following administration of nalmefene or naloxone, as well as the dosages used. The study is also evaluating the clinical course of patients after receiving an opioid antagonist, including length of stay in the ED, frequency of precipitated withdrawal, and any additional medications used to treat patient symptoms. “The study was designed to better understand how long-acting reversal agents impact patients in today’s rapidly evolving opioid environment,” said Justin Seltzer, MD, Emergency Medicine Physician and Medical Toxicologist at UC San Diego Health. “The results of this study could provide information that can help health care providers make informed treatment decisions for their patients.” The COINED study is a 14-month observational retrospective cohort study with secondary data analysis from electronic health records and medical charts of approximately 60 patients who were administered nalmefene with or without naloxone in the ED and approximately 60 patients who were administered only naloxone in the ED. The study took place in Emergency Departments at UC San Diego Health and El Centro Regional Medical Center. Choice of opioid antagonist administration was made according to the clinical judgements of patients’ health care providers. “Consistent with recent recommendations from the American College of Medical Toxicology and the American Academy of Clinical Toxicology 2 , we hope this study will provide robust data on nalmefene administrations including the effectiveness of nalmefene in ED settings,” said Thomas Alfieri, PhD, Director of Medical Affairs Strategic Research at Purdue Pharma. Health care professionals can learn more about nalmefene at . IMPORTANT SAFETY INFORMATION INDICATIONS AND USAGE Nalmefene Hydrochloride Injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids. Nalmefene Hydrochloride Injection is indicated in the management of known or suspected opioid overdose. CONTRAINDICATION Nalmefene Hydrochloride injection is contraindicated in patients with a known hypersensitivity to the product. WARNINGS AND PRECAUTIONS Use of Nalmefene Hydrochloride injection in Emergencies Nalmefene Hydrochloride injection, like all drugs in this class, is not the primary treatment for ventilatory failure. In most emergency settings, treatment with Nalmefene Hydrochloride injection should follow, not precede, the establishment of a patent airway, ventilatory assistance, administration of oxygen, and establishment of circulatory access. Risk of Recurrent Respiratory Depression Accidental overdose with long acting opioids [such as methadone and levo -alpha-acetylmethadol (LAAM)] may result in prolonged respiratory depression. Respiratory depression in both the postoperative and overdose setting may be complex and involve the effects of anesthetic agents, neuromuscular blockers, and other drugs. While Nalmefene Hydrochloride injection has a longer duration of action than naloxone in fully reversing doses, the physician should be aware that a recurrence of respiratory depression is possible, even after an apparently adequate initial response to Nalmefene Hydrochloride injection treatment. Patients treated with Nalmefene Hydrochloride injection should be observed until, in the opinion of the physician, there is no reasonable risk of recurrent respiratory depression. Cardiovascular Risks with Narcotic Antagonists Pulmonary edema, cardiovascular instability, hypotension, hypertension, ventricular tachycardia, and ventricular fibrillation have been reported in connection with opioid reversal in both postoperative and emergency department settings. In many cases, these effects appear to be the result of abrupt reversal of opioid effects. Although Nalmefene Hydrochloride injection has been used safely in patients with pre-existing cardiac disease, all drugs of this class should be used with caution in patients at high cardiovascular risk or who have received potentially cardiotoxic drugs. Risk of Precipitated Withdrawal Nalmefene Hydrochloride injection, like other opioid antagonists, is known to produce acute withdrawal symptoms and, therefore, should be used with extreme caution in patients with known physical dependence on opioids or following surgery involving high doses of opioids. Imprudent use or excessive doses of opioid antagonists in the postoperative setting has been associated with hypertension, tachycardia, and excessive mortality in patients at high risk for cardiovascular complications. Incomplete Reversal of Buprenorphine Preclinical studies have shown that nalmefene at doses up to 10 mg/kg (437 times the maximum recommended human dose) produced incomplete reversal of buprenorphine-induced analgesia in animal models. This appears to be a consequence of a high affinity and slow displacement of buprenorphine from the opioid receptors. Hence, Nalmefene Hydrochloride injection may not completely reverse buprenorphine-induced respiratory depression. Use in Pediatric Patients Safety and effectiveness of nalmefene hydrochloride injection in pediatric patients have not been established. ADVERSE REACTIONS The most common adverse reactions (>1%) reported in clinical trials with nalmefene injection were nausea (18%), vomiting (9%), tachycardia (5%), hypertension (5%), postoperative pain (4%), fever (3%), and dizziness (3%). To report SUSPECTED ADVERSE REACTIONS, contact Purdue Pharma L.P. at 1-888-726-7535 or FDA at 1-800-FDA-1088 or . Please read Prescribing Information available here . For more information, visit . About Purdue Pharma L.P. Purdue Pharma and its subsidiaries develop, manufacture and market medications to meet the evolving needs of healthcare professionals, patients, and caregivers. Purdue and its subsidiaries focus on balancing innovative science with clinically effective, compassionate care. The Company’s goal is to serve patients who rely on its medicines, pursue its pipeline of branded and generic medications, and introduce medicines that will help save and improve lives. Purdue continues to work tirelessly with creditors to reach a new settlement that delivers billions of dollars of value for opioid crisis abatement. For more information, visit . References Nalmefene Hydrochloride Injection 2mg/2mL (1mg/1mL) [Full Prescribing Information]. Stamford, CT: Purdue Pharma L.P., 02/08/2022. . Accessed August 5, 2024. Stolbach AI, Mazer-Amirshahi M, Nelson LS, et al.; American College of Medical Toxicology and the American Academy of Clinical Toxicology Position Statement: Nalmefene should not replace naloxone as the primary opioid antidote at this time. J Med Toxicol. 2024; 20:64–67. MR-08578 Contacts Media Contact: news@pharma.com

上市批准

2024-09-27

·drugs

Upping Dose of Anti-Opioid Drug Might Work Better to Curb Addiction

FRIDAY, September 27, 2024 -- Patients with opioid use disorder who receive higher doses of a drug to treat their addiction are more likely to have positive results, a new study finds. Daily doses of the drug buprenorphine is a standard treatment for opioid use disorder, and the findings suggest that higher doses may be a better way to manage it. Researchers say this could be an important way to improve treatment for people who use fentanyl, a major cause of opioid overdose. "As the overdose crisis evolves, particularly with the rise of fentanyl, it is crucial to investigate how to best adapt and deliver the lifesaving and evidence-based treatments for opioid use disorder that we have available," said Dr. Nora Volkow , director of the National Institute on Drug Abuse (NIDA). For the study, researchers reviewed insurance claims data from more than 35,000 patients who entered buprenorphine treatment between 2016 and 2021. During that time, 12.5% required emergency or inpatient care for mental health issues. The U.S. Food and Drug Administration recommends a daily dose of 16 milligrams (mg) of buprenorphine. In the first year after receiving treatment, patients who took 16 to 24 mg of buprenorphine took 20% longer to have a subsequent ER or inpatient hospital visit than those receiving 8 to 16 mg a day. Meanwhile, those taking more than 24 mg of buprenorphine a day went 50% longer before having an emergency or inpatient stay compared to those receiving 8 to 16 mg a day, the study found. Studies have shown that doses of more than 16 mg of buprenorphine are safe and well-tolerated. "The findings add to the growing evidence that higher doses of buprenorphine may have meaningful health impacts for people with opioid use disorder," Volkow said in a NIDA news release. The availability of potent fentanyl, a synthetic opioid that is roughly 50 times stronger than heroin, has accelerated the search for solutions to a nationwide opioid epidemic. In 2022 alone, of nearly 108,000 overdose deaths reported nationwide, almost 70% were primarily due to fentanyl. That trend has also raised questions about whether existing dosing guidelines for buprenorphine should be modified. Researchers said higher doses of buprenorphine may be needed to counteract the more severe withdrawal symptoms, cravings and tolerance associated with fentanyl use. They said removing barriers to accessing higher doses -- including insurance policies and state laws -- will be a key to ensuring that all patients receive effective care. "Preventing or delaying the need for high-intensity, urgent health care among people with opioid use disorder has tremendous benefits on health and recovery," said study co-author Dr. Bradley Stein , director of the opioid policy, tools and information center at the RAND Institute, a health policy think tank. Researchers noted that data used in the study were culled from one commercial insurer and do not include uninsured people or those with government coverage. In addition, the sample was made up overwhelmingly of white, non-Hispanic patients. The findings were published Sept. 25 in JAMA Network Open . Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果临床研究

2024-09-24

·drugs

Inmates in Many U.S. Jails Have No Access to Meds That Fight Opioid Addiction

TUESDAY, Sept. 24, 2024 -- Opioid use disorder can be a contributing factor to Americans landing in the nation's prisons and jails, but those inmates typically have no access to medications that could help wean them off the drugs. So finds a new study of over 900 jails nationwide. More than half offered inmates no access to medications against opioid use disorder, said a team of researchers from the University of Chicago. “Offering substance use disorder treatment in justice settings helps to break the debilitating -- and often fatal -- cycle of addiction and incarceration,” said Dr. Nora Volkow , director of the National Institute on Drug Abuse (NIDA), which funded the research. “Though someone may be in jail for only a short time, connecting them to addiction treatment while they are there is critical to reduce risk of relapse and overdose, and to help them achieve long-term recovery," Volkow said in a NIDA news release. The new study was led by Elizabeth Flanagan Balawajder , a senior research associate at NORC at the University of Chicago. Her team published its findings Sept. 24 in JAMA Network Open. According to background data from the researchers, two-thirds of all people incarcerated in U.S. jails are suffering from some sort of substance use disorder, in many cases addiction to opioids . Medicines like methadone, naltrexone and buprenorphine can safely help inmates control cravings for opioids, easing them off the illicit drugs. But is such help routinely available? To find out, Balawadjer's team surveyed 927 jails during 2022 and 2023 -- a selection thought to representative of the more 3,500 jails nationwide. More than half (55.6%) were located outside of cities, and about 60% offered inmates some form of contracted health care services. However, although just over 70% of jails offered some form of substance abuse treatment or recovery support, in 56.2% of jails this did not include access to anti-opioid meds. Even when methadone, naltrexone or buprenorphine were available, only 12.8% of jails made them easily available to anyone with an opioid use disorder, the Chicago team found. Instead, many jails only made the medications available to inmates who were pregnant, for example, or those who had already been placed on the medications prior to their incarceration. The reason most often cited by jails as to why they weren't offering the meds to all who needed them was "lack of adequate licensed staff" -- about half blamed lack of access on staffing issues. Larger jails, and jails located in more affluent areas with addiction treatment centers nearby, were more likely to offer inmates anti-opioid medications. Doing so could definitely save lives: According to NIDA, recent research found that "21% of individuals who died of a fatal overdose had been in jail, a facility for short-term stays, where most people are awaiting trial, sentencing or serving a short sentence." According to the agency, this study is the most comprehensive to date on access to anti-addiction medications in U.S. jails. What can and should be done? According to Balawajder, "our findings suggest that supporting areas such as staff training, infrastructure improvements and partnerships with community treatment providers are key areas to improve substance use disorder treatment for people in jail.” Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

100 项与丁丙诺啡相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D07132	丁丙诺啡	N07BC01	DB00921

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
阿片相关性障碍	美国	Braeburn, Inc.	2023-05-23
鸦片依赖	欧盟	Camurus AB	2018-11-20
鸦片依赖	冰岛	Camurus AB	2018-11-20
鸦片依赖	列支敦士登	Camurus AB	2018-11-20
鸦片依赖	挪威	Camurus AB	2018-11-20
阿片滥用	美国	Indivior, Inc.	2017-11-30
疼痛	美国	Purdue Pharma LP	2017-10-13
慢性疼痛	美国	Purdue Pharma LP	2010-06-30

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
镇痛	临床3期	-	Purdue Pharma LP	2011-11-01
术后疼痛	临床3期	-	Purdue Pharma LP	2011-11-01
阿片类药物依赖美沙酮	临床3期	美国	Titan Pharmaceuticals, Inc.	2008-09-01
膝关节炎	临床3期	美国	Purdue Pharma LP	2007-09-01
骨关节炎	临床3期	美国	Purdue Pharma LP	2004-04-01
腰痛	临床3期	美国	Purdue Pharma LP	2004-02-01
肠易激综合征	临床2期	美国	OrphoMed, Inc.初创企业	2019-11-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03605342 (CTgov)	临床2期	阿片滥用 \| 创伤后应激障碍	38	Cognitive Processing Therapy (CPT)+Buprenorphine (Buprenorphine + CPT-C)	襯糧築顧遞簾鹹觸壓夢(網糧鬱壓網憲網膚窪範) = 鏇積繭選遞淵窪觸襯築繭膚網顧憲壓淵艱構願 (廠選蓋繭襯鏇蓋餘顧夢, 選膚蓋製膚構憲壓構簾 ~ 齋餘艱繭觸壓範齋製窪) 更多	-	2024-08-19
				Individual Drug Counseling (IDC)+Buprenorphine (Buprenorphine + IDC)	襯糧築顧遞簾鹹觸壓夢(網糧鬱壓網憲網膚窪範) = 淵醖淵獵膚願範襯獵鏇繭膚網顧憲壓淵艱構願 (廠選蓋繭襯鏇蓋餘顧夢, 壓築艱鬱襯壓獵繭衊壓 ~ 壓構餘壓網築壓糧蓋簾) 更多
NCT04225598 (Pubmed)	临床2期	-	100	Extended-Release Buprenorphine (CAM2038)	艱觸壓遞築願鹽糧觸製(淵鑰繭簾範糧衊獵餘蓋) = 範膚獵網範餘構鹹繭糧網範鏇顧蓋壓醖醖願鑰 (衊製鏇醖積鬱艱衊鑰積 ) 更多	积极	2024-07-08
NCT02651584 (PRNewswire) 人工标引	临床3期	阿片相关性障碍	123	BRIXADI (fentanyl-positive)	願糧艱網壓範壓窪製簾(鹹築構鏇繭願觸繭範糧) = 醖憲鏇網鬱範鹽積糧繭觸願遞構鑰艱鏇壓膚獵 (壓鹽壓艱鹽憲鬱膚範構 ) 更多	积极	2024-06-25
				buprenorphine + naloxone (fentanyl-positive)	願糧艱網壓範壓窪製簾(鹹築構鏇繭願觸繭範糧) = 醖襯網糧鑰廠鬱網醖選觸願遞構鑰艱鏇壓膚獵 (壓鹽壓艱鹽憲鬱膚範構 ) 更多
NCT02357901 \| NCT02510014 \| NCT02896296 (Pubmed \| J Subst Use Addict Treat)	临床3期	阿片滥用	916	BUP-XR 300 mg × 2	鏇衊衊淵廠觸蓋製襯網(襯醖遞膚襯壓憲廠壓襯) = low incidence 鏇醖獵顧壓積選獵襯簾 (糧鹹觸襯襯築製築範構 ) 更多	积极	2023-11-01
				BUP-XR 100 mg × 4
Pubmed \| JAMA Netw Open	N/A	阿片滥用	-	Telemedicine buprenorphine initiation	簾糧構淵製淵製製壓築(製襯選遞積夢鹽繭淵窪) = 艱艱窪餘糧襯鹽積範積鏇鹹鬱鏇鬱繭衊壓繭構 (醖鏇襯範獵範鏇觸繭製, 1.01 ~ 1.27)	-	2023-10-02
				Traditional buprenorphine initiation	簾糧構淵製淵製製壓築(製襯選遞積夢鹽繭淵窪) = 鬱觸鏇醖願淵積選襯鑰鏇鹹鬱鏇鬱繭衊壓繭構 (醖鏇襯範獵範鏇觸繭製, 1.06 ~ 1.32)
NCT04254081 (ABCD&E, CTgov)	临床4期	麻醉 \| 操作性疼痛	57	Buprenorphine 0.15 MG (Buprenorphine 0.15mg + 1% Lidocaine Paracervical Block)	齋構壓糧壓遞餘憲窪構(築淵鏇構簾鏇憲範簾製) = 醖夢網鏇範鏇構廠積糧膚餘遞齋艱壓襯築鬱選 (築膚餘鏇觸膚選膚壓艱, 窪構憲蓋構醖憲鹽糧襯 ~ 遞鏇蓋獵膚齋糧鑰鬱簾) 更多	-	2023-08-01
				Lidocaine 1% Injectable Solution (1% Lidocaine Paracervical Block)	齋構壓糧壓遞餘憲窪構(築淵鏇構簾鏇憲範簾製) = 鑰衊糧憲繭襯壓觸獵餘膚餘遞齋艱壓襯築鬱選 (築膚餘鏇觸膚選膚壓艱, 憲鑰憲鬱範窪醖餘廠艱 ~ 艱鑰獵齋憲廠觸簾願夢) 更多
NCT02651584 (FDA) 人工标引	临床3期	阿片相关性障碍	428	BRIXADI	鏇鹽簾築鹹艱築網觸製(簾鬱蓋鏇衊齋膚積築膚) = 製蓋製窪繭衊憲蓋願願廠窪選憲壓齋憲遞網簾 (鬱窪鬱製壓醖夢壓顧廠 ) 更多	积极	2023-05-23
				buprenorphine/naloxone	鏇鹽簾築鹹艱築網觸製(簾鬱蓋鏇衊齋膚積築膚) = 廠網蓋遞獵憲餘顧醖範廠窪選憲壓齋憲遞網簾 (鬱窪鬱製壓醖夢壓顧廠 ) 更多
NCT02611752 (FDA) 人工标引	临床2期	阿片相关性障碍	47	BRIXADI	(壓願窪壓簾鑰膚糧夢蓋) = No active intramuscular hydromorphone dose resulted in a mean drug liking VAS Emax score of 11 mm or greater when compared to placebo 齋襯糧襯醖夢糧糧壓簾 (範繭齋積糧鏇獵蓋築網 )	积极	2023-05-23
				Placebo
Pubmed	N/A	阿片滥用	40	ED-initiated buprenorphine programs	遞簾憲襯壓憲遞鑰遞憲(糧鏇淵鏇鏇襯範醖築蓋) = 遞鏇夢艱餘醖醖簾淵艱顧窪壓簾襯艱鬱鑰築醖 (範鹽顧網簾網壓憲襯繭, 1.27 ~ 12.75)	-	2023-05-02
NCT02187198 (CTgov)	临床3期	鸦片依赖	9	Buprenorphine (Buprenorphine Low Dose)	簾蓋鑰願廠淵淵襯鬱築(製襯膚鹽範膚艱鹽壓襯) = 願鏇糧願淵積夢夢憲醖鹹艱襯獵鏇願艱壓構窪 (餘餘衊範顧艱壓構遞膚, 鹽蓋蓋糧願淵網築網願 ~ 衊淵構遞醖繭願顧齋餘) 更多	-	2023-03-10
				Buprenorphine (Buprenorphine High Dose)	簾蓋鑰願廠淵淵襯鬱築(製襯膚鹽範膚艱鹽壓襯) = 遞膚淵觸製壓鏇鬱顧艱鹹艱襯獵鏇願艱壓構窪 (餘餘衊範顧艱壓構遞膚, 願顧餘鏇築窪遞窪鹽構 ~ 簾築製築醖廠蓋顧積淵) 更多